Clinical Trial

Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom

Study acronym: CHAMP-UK
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 7, 2023 (before its estimated February 29, 2024 completion). Its status may not reflect the trial's current state.
Summary
Short-sightedness, also called myopia, makes objects in the distance, such as the television, look blurred. This is caused by the eye growing too long, something that usually happens while children are also getting taller. People with myopia can see better with glasses or contact lenses, but this doesn't stop their eyes continuing to become more short-sighted. The CHAMP UK study is investigating a type of eye drop called atropine that might help to stop myopia getting worse as children get older.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-09-27; most recent amendment 2023-09-06.
Status change: Recruiting → Active, Not Recruiting 2022-04-14
Status change: Not Yet Recruiting → Recruiting 2019-07-10
Trial Details
NCT Number NCT03690089
Lead Sponsor Belfast Health and Social Care Trust
Conditions Myopia
Enrollment 289 participants
Start Date 2019-04-03
Primary Completion 2024-02-29 (estimated)
Study Completion 2027-02-02 (estimated)
Updated on ClinicalTrials.gov 2023-09-07